NDA 021687 · Organon
Vytorin
Ezetimibe, Simvastatin · Oral · Dietary Cholesterol Absorption Inhibitor; HMG-CoA Reductase Inhibitor
Last checked: Nov 20, 2026Latest source record: Mar 28, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2004
Jul 23, 2004
Approved uses
5
Original approval plus efficacy supplements
Registered trials
422
153 Phase 3, 37 recruiting
FAERS reports
15,138
9,500 serious, 857 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 21, 2026.
VYTORIN VYTORIN ® is a combination of simvastatin and ezetimibe indicated: As an adjunct to diet to reduce elevated low density lipoprotein cholesterol (LDL-C): In adults with primary hyperlipidemia. In adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to other LDL-C-lowering therapies to reduce elevated LDL-C in adults with homozygous familial hypercholesterolemia (HoFH). Simvastatin Simvastatin, when used as a component of VYTORIN, is indicated to reduce the risk of total mortality by reducing risk of coronary heart disease death, non-fatal myocardial infarction and stroke, and the need for coronary and non-coronary revascularization procedures in adults with established coronary heart disease, cerebrovascular disease, peripheral vascular disease, and/or diabetes, who are at high risk of coronary heart disease events. VYTORIN is a combination of ezetimibe, a dietary cholesterol absorption inhibitor, and simvastatin, an HMG-CoA reductase inhibitor (statin) indicated: ( 1 ) As an adjunct to diet to reduce elevated low density lipoprotein cholesterol (LDL-C): In adults with primary hyperlipidemia. In adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to other LDL-C lowering therapies to reduce LDL-C in adults with homozygous familial hypercholesterolemia (HoFH). Simvastatin Simvastatin, when used as a component of VYTORIN, is indicated to reduce the risk of total mortality by reducing risk of coronary heart disease death, non-fatal myocardial infarction and stroke, and the need for coronary and non-coronary revascularization procedures in adults with established coronary heart disease, cerebrovascular disease, peripheral...
Mechanism: VYTORIN Plasma cholesterol is derived from intestinal absorption and endogenous synthesis. VYTORIN contains ezetimibe and simvastatin, two lipid-lowering compounds with complementary mechanisms of action. Ezetimibe Ezetimibe reduces blood cholesterol by inhibiting the absorption of cholesterol by the small intestine. The molecular target of ezetimibe has been shown to be the sterol transporter, Niemann-Pick C1-Like 1 (NPC1L1), which is involved in the intestinal uptake of cholesterol and phytosterols. Ezetimibe localizes at the brush border of the small intestine and inhibits the absorption...
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 24, 2012 Supplement 39 · Efficacy LabelLetter
- Jun 13, 2008 Supplement 23 · Efficacy · priority review
- Oct 3, 2006 Supplement 11 · Efficacy LabelLetter
- Mar 16, 2006 Supplement 6 · Efficacy LabelLetter
- Jul 23, 2004 Original approval · Type 4 - New Combination Other Important Information from FDAPediatric Medical ReviewPediatric Clinical Pharmacology Review
4 products under this application
- VYTORIN · EZETIMIBE 10MG; SIMVASTATIN 80MG · TABLET, ORAL · Prescription · TE AB
- VYTORIN · EZETIMIBE 10MG; SIMVASTATIN 20MG · TABLET, ORAL · Prescription · TE AB
- VYTORIN · EZETIMIBE 10MG; SIMVASTATIN 40MG · TABLET, ORAL · Prescription · TE AB
- VYTORIN · EZETIMIBE 10MG; SIMVASTATIN 10MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Ezetimibe" as an intervention, any sponsor and status, largest first.
- Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVEPivotal-lookingCompleted
University of OxfordAcademic, hospital or other
NCT00461630 · 25,673 participants · Start Jan 2007 · Primary completion Oct 2012
Drug: ER niacin/laropiprant; simvastatin and 1 more · For: Cardiovascular Disease; Peripheral Arterial Disease; Diabetes Mellitus and 1 more
Sites: Oxford, United Kingdom
- IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00202878 · 18,144 participants · Start Oct 17, 2005 · Primary completion Sep 18, 2014
Drug: ezetimibe/simvastatin; simvastatin and 2 more · For: Hypercholesterolemia; Myocardial Infarction
- Study of Heart and Renal ProtectionPivotal-lookingCompleted
University of OxfordAcademic, hospital or other
NCT00125593 · 9,438 participants · Start Jun 2003 · Primary completion Aug 2010
Drug: Simvastatin 20 mg; Ezetimibe 10mg and 1 more · For: Kidney Disease, Chronic
Sites: Oxford, United Kingdom
- Polypills Approach for Multiple Cardiovascular Risk FactorsPivotal-lookingRecruiting
China Medical University, ChinaAcademic, hospital or other
NCT07679828 · 8,252 participants (planned) · Start Jul 11, 2026 · Primary completion Dec 31, 2029
Drug: Fixed-Dose Combination Strategy · For: Hypertension; Dyslipidemia; Diabetes
Sites: Zhengzhou, China; Chifeng, China; Tongliao, China · 15 sites in all
- A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on StatinPivotal-lookingCompleted
Amarin Pharma Inc.Industry
NCT01492361 · 8,179 participants · Start Nov 2011 · Primary completion May 2018
Drug: AMR101; Placebo and 1 more · For: Cardiovascular Diseases
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 410 sites in all
- GUIDE-CAC: Statin-Ezetimibe Without Aspirin vs. Statin Monotherapy With Aspirin in High Coronary CalcificationPivotal-lookingRecruiting
Asan Medical CenterAcademic, hospital or other
NCT06722521 · 7,435 participants (planned) · Start Jul 9, 2025 · Primary completion Jun 30, 2032
Drug: Pitavastatin 4mg and ezetimibe 10mg, taken once daily; Pitavastatin 2 mg with aspirin 100 mg, taken once daily. · For: Primary Prevention; Vascular Calcification
Sites: Seoul, South Korea
Saint Vincent's Hospital, KoreaAcademic, hospital or other
NCT06186037 · 6,356 participants (planned) · Start Feb 1, 2024 · Primary completion Feb 28, 2029
Drug: Combination drug group of Ezetimibe 10 mg/Rosuvastatin 5 mg; Mono drug group of Rosuvastatin 20 mg · For: Coronary Artery Disease; Dyslipidemias; Primary Prevention
Sites: Suwon, South Korea
- Multifactorial Intervention on Diabetes (MIDiab Study)Pivotal-lookingStatus unknown
Shandong Provincial HospitalGovernment (non-federal)
NCT03430284 · 6,300 participants (planned) · Start Apr 1, 2018 · Primary completion Dec 31, 2021
Drug: Pharmacotherapy · For: Diabetes Mellitus, Type 2
Sites: Jinan, China · 2 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea1,013
- drug ineffective821
- fatigue777
- dizziness734
- pain708
- myalgia675
- dyspnoea647
- diarrhoea605
- asthenia604
- headache566
- pain in extremity550
- arthralgia533
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 40 |
| 2005 | 627 |
| 2006 | 949 |
| 2007 | 1,301 |
| 2008 | 1,554 |
| 2009 | 1,189 |
| 2010 | 1,679 |
| 2011 | 1,130 |
| 2012 | 987 |
| 2013 | 801 |
| 2014 | 830 |
| 2015 | 912 |
| 2016 | 751 |
| 2017 | 563 |
| 2018 | 447 |
| 2019 | 407 |
| 2020 | 250 |
| 2021 | 197 |
| 2022 | 132 |
| 2023 | 97 |
| 2024 | 98 |
| 2025 | 110 |
| 2026 | 87 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Vytorin (Ezetimibe/Simvastatin)
2024 spending
$4.3M
Beneficiaries
1,203
5,246 claims
Per beneficiary
$3,572
$12.40 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $1,767,362 |
| 2022 | $5,606,613 |
| 2023 | $5,039,586 |
| 2024 | $4,297,632 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
Cannon CP, Blazing MA, Giugliano RP, et al. · N Engl J Med 2015 · Comparative Study, Multicenter Study
- PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis.
Khan SU, Yedlapati SH, Lone AN, et al. · BMJ 2022 · Systematic Review, Network Meta-Analysis
- Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial.
Kim BK, Hong SJ, Lee YJ, et al. · Lancet 2022 · Randomized Controlled Trial, Equivalence Trial
- Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.
Ballantyne CM, Laufs U, Ray KK, et al. · Eur J Prev Cardiol 2020 · Clinical Trial, Phase III, Multicenter Study
- Lipid-Lowering Therapy and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Bétrisey S, Haller ML, Efthimiou O, et al. · J Am Heart Assoc 2024 · Meta-Analysis, Systematic Review
- The clinical effectiveness and safety of low/moderate-intensity statins & ezetimibe combination therapy vs. high-intensity statin monotherapy: a systematic review and meta-analysis.
Sydhom P, Al-Quraishi B, El-Shawaf M, et al. · BMC Cardiovasc Disord 2024 · Systematic Review, Meta-Analysis
Sponsor: Organon
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.